Proteogenomics reveals markers of chemotherapy resistance and outcome in triple negative breast cancer
Broad Institute
AUGUST 24, 2022
Data from standard DNA and RNA sequencing approaches were integrated with mass spectrometry-based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive versus treatment-resistant tumors.
Let's personalize your content